General and Modular Strategy for Designing Potent, Selective, and Pharmacologically Compliant Inhibitors of Rhomboid Proteases
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Rhomboid-family intramembrane proteases regulate important biological processes and have been associated with malaria, cancer, and Parkinson's disease. However, due to the lack of potent, selective, and pharmacologically compliant inhibitors, the wide therapeutic potential of rhomboids is currently untapped. Here, we bridge this gap by discovering that peptidyl α-ketoamides substituted at the ketoamide nitrogen by hydrophobic groups are potent rhomboid inhibitors active in the nanomolar range, surpassing the currently used rhomboid inhibitors by up to three orders of magnitude. Such peptidyl ketoamides show selectivity for rhomboids, leaving most human serine hydrolases unaffected. Crystal structures show that these compounds bind the active site of rhomboid covalently and in a substrate-like manner, and kinetic analysis reveals their reversible, slow-binding, non-competitive mechanism. Since ketoamides are clinically used pharmacophores, our findings uncover a straightforward modular way for the design of specific inhibitors of rhomboid proteases, which can be widely applicable in cell biology and drug discovery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
Irreversible Inhibitors of Serine, Cysteine, and Threonine Proteases
Powers, J. C., Asgian, J. L., Ekici, Ö. D., & James, K. E. (2002) · Chemical Reviews · doi:10.1021/cr010182v · Cited by 1,090
Cited by
Mitophagy in the pathogenesis and management of disease
Wang, Q., Sun, Y., Li, T. Y., & Auwerx, J. (2026) · Cell Research · doi:10.1038/s41422-025-01203-7 · Cited by 103
Began, J., Cordier, B., Březinová, J., Delisle, J., Hexnerová, R., Srb, P., Rampírová, P., Kožíšek, M., Baudet, M., Couté, Y., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2019102935 · Cited by 55
“While deletion of CTD ( D 388 – 507, D CTD) seems to have led to about four-to sixfold increase in YqgP activity for both substrates, deletion of NTD ( D 1 – 178, D NTD) reduced YqgP activity for MgtE threefold, but only marginally so for the model TatA substrate (Fig 4A).”
InfluentialSelf-citationThe discovery of proteases and intramembrane proteolysis
Paschkowsky, S., Hsiao, J. M., Young, J. C., & Munter, L. M. (2019) · Biochemistry and Cell Biology · doi:10.1139/bcb-2018-0186 · Cited by 14
Metadata
- Authors
- Tichá, A., Stanchev, S., Vinothkumar, K. R., Mikles, D. C., Pachl, P., Began, J., Škerle, J., Švehlová, K., Nguyen, M. T. N., Verhelst, S. H. L., Johnson, D. C., Bachovchin, D. A., Lepšík, M., Majer, P., & Strisovsky, K.
- Venue
- Cell Chemical Biology
- Publisher
- Elsevier BV
- Published
- 2017-12
- Volume
- 24
- Issue
- 12
- Pages
- 1523-1536.e4
- ISSN
- 2451-9448 (ISSN-L)
- 2451-9456
- OpenAlex
- W2765435674
- Cited by
- 53
- References
- 2
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.